Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes

Trial Profile

Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
  • Indications Cervical cancer; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jul 2017 Planned primary completion date changed from 31 Dec 2018 to 4 Dec 2028.
    • 20 Jul 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2029.
    • 05 Oct 2016 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top